Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| E EnginZymeCompany profile EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. | SEK 75M | Equity roundUndisclosed | Biotech | Sweden | Investors | |
| TT Tempo TherapeuticsCompany profile A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. | ≤$2.3M | NCI SBIR grantUndisclosed | Biotech | United States | Investors | |
| BR Basecamp ResearchCompany profile Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. | $140M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| E EnvedaCompany profile Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. | $311M | Series ESeries C+ | Biotech | United States | Investors | |
| AL Azulene LabsCompany profile Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. | $3.4M | Pre-SeedPre-seed | Biotech | — | Investors | |
| PB Primrose BioCompany profile Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. | Undisclosed | Growth financingGrowth | Biotech | United States | Investors | |
| C CellsBinCompany profile A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. | Undisclosed | Series A | Biotech | United States | Investors | |
| MT Molecular Targeting Technologies, Inc.Company profile A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. | $3.2M | National Cancer Institute R01 grantUndisclosed | Biotech | United States | Investors | |
| I ImpriMedCompany profile A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient. A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient. | $10M | Series A2 bridgeUndisclosed | Biotech, Healthtech | South Korea | Investors | |
| AB Axio BioPharmaCompany profile A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records. A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records. | $2.4M | Pre-seed | Biotech, Enterprise software | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.